Results 101 to 110 of about 21,815 (182)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

open access: yesProstate Cancer, 2017
We examined the comparative efficacies of first-line abiraterone and enzalutamide in pre- and postdocetaxel settings in castration-resistant prostate cancer (CRPC) through a trial level meta-analysis.
Mike Fang   +3 more
doaj   +1 more source

Primary BPH Stromal Cell Cultures Exhibit Heightened Androgen‐Responsiveness

open access: yesThe Prostate, Volume 86, Issue 15, Page 1508-1517, November 2026.
ABSTRACT Background Benign prostatic hyperplasia (BPH) is the most common disease in aging males. BPH growth is androgen‐dependent, and it appears that androgens preferentially stimulate the growth of BPH as compared to normal prostate. The mechanism of preferential androgen stimulation of BPH growth is not clear.
Wei Chen   +9 more
wiley   +1 more source

Zhoushi Qiling decoction inhibits neuregulin 1 secreted from cancer-associated fibroblasts to ameliorate enzalutamide resistance in prostate cancer

open access: yesJournal of Traditional and Complementary Medicine
Background and aim: Zhoushi Qiling decoction (ZQD) has emerged as a promising therapeutic agent for improving outcomes in prostate cancer treatment. This study aimed to evaluate the efficacy of ZQD on enzalutamide-resistant prostate cancer cells and to ...
Chunyu Wang   +5 more
doaj   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

open access: yesCancer Science, Volume 117, Issue 11, Page 3086-3097, November 2026.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota   +8 more
wiley   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

open access: yesImmunology &Cell Biology, Volume 104, Issue 10, Page 996-1014, November‐December 2026.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Natural Product‐Induced Ferroptosis to Overcome Therapy Resistance in Aggressive Cancers

open access: yesChemMedChem, Volume 21, Issue 20, 28 October 2026.
Natural products trigger ferroptosis through iron overload, glutathione depletion, glutathione peroxidase 4 inhibition, and reactive oxygen species accumulation, selectively targeting aggressive, and drug‐resistant cancers. Polyphenols, alkaloids and terpenoids emerge as promising multi‐target agents to overcome therapy resistance and improve future ...
Giorgio Antoniolli
wiley   +1 more source

LGR5 interacts with HSP90AB1 to mediate enzalutamide resistance by activating the WNT/β-catenin/AR axis in prostate cancer

open access: yesChinese Medical Journal
. Background:. Enzalutamide, a second-generation androgen receptor (AR) pathway inhibitor, is widely used in the treatment of castration-resistant prostate cancer.
Ze Gao   +7 more
doaj   +1 more source

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

open access: yesHealth and Quality of Life Outcomes, 2017
Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Patients received
Nancy Devlin   +11 more
doaj   +1 more source

Investigating aberrant signalling in enzalutamide-resistant prostate cancer [PDF]

open access: yes, 2017
PhD ThesisProstate cancer is usually androgen-dependent and consequently, initial therapy for many patients, particularly with advanced disease, is androgen withdrawal, via anti-androgen therapeutics. Most patients respond to anti-androgen therapy in the
Alsamraae, Massar Ibrahim Shekhan
core  

Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism

open access: yesCell Death and Disease
Enzalutamide, as a second-generation anti-androgen agent, has been used to treat castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC).
Yi Zhou   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy